文献速递骨质疏松与代谢性骨病

吡格列酮对骨密度与骨髓脂肪含量的影响

Impact of pioglitazone on bone mineral density and bone marrow fat content.
PubMed 文献 · Osteoporos Int · 2017-07-22

这项随机、安慰剂对照试验纳入42例代谢综合征肥胖志愿者,吡格列酮45 mg/日或安慰剂治疗1年。12个月时吡格列酮组股骨颈骨髓脂肪增加(+4.1%,p=0.03),全髋骨密度下降(-1.4%),且骨髓脂肪变化以女性为主。

要点

  • 吡格列酮治疗12个月与股骨颈骨髓脂肪含量显著增加相关(绝对变化+4.1%,p=0.03)。
  • 吡格列酮组全髋骨密度下降1.4%,安慰剂组升高0.8%,组间p=0.03。
  • 吡格列酮组全髋骨密度变化与骨髓脂肪变化呈显著负相关(Spearman rho=-0.56,p=0.01)。

核心结论

  • 与安慰剂相比,吡格列酮使用12个月与股骨颈骨髓脂肪含量显著增加相关,并伴随全髋骨密度小幅但显著的下降。

研究设计与样本

  • 双盲安慰剂对照临床试验,42例代谢综合征肥胖志愿者随机接受吡格列酮45 mg/日或匹配安慰剂治疗1年。
  • 37例完成基线和1年评估并纳入结果分析。

主要发现

  • 12个月时吡格列酮组骨髓脂肪增加(绝对变化+4.1%,p=0.03),安慰剂组非显著下降(-3.1%,p=0.08),两组反应差异p=0.007。
  • 吡格列酮组全髋骨密度下降1.4%,安慰剂组升高0.8%,组间p=0.03。
  • 吡格列酮组全髋骨密度变化与骨髓脂肪变化呈显著负相关(Spearman rho=-0.56,p=0.01),安慰剂组无显著相关(rho=-0.29,p=0.24)。
  • 吡格列酮相关的骨髓脂肪变化主要在女性受试者中观察到,男性中较少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Pioglitazone use is associated with an increased risk of fractures. In this randomized, placebo-controlled study, pioglitazone use for 12 months was associated with a significant increase in bone marrow fat content at the femoral neck, accompanied by a significant decrease in total hip bone mineral density. The change in bone marrow fat with pioglitazone use was predominantly observed in female vs. male participants. INTRODUCTION: Use of the insulin sensitizer pioglitazone is associated with greater fracture incidence, although the underlying mechanisms are incompletely understood. This study aimed to assess the effect of pioglitazone treatment on femoral neck bone marrow (BM) fat content and on bone mineral density (BMD), and to establish if any correlation exists between the changes in these parameters. METHODS: In this double-blind placebo-controlled clinical trial, 42 obese volunteers with metabolic syndrome were randomized to pioglitazone (45 mg/day) or matching placebo for 1 year. The following measurements were conducted at baseline and during the treatment: liver, pancreas, and femoral neck BM fat content (by magnetic resonance spectroscopy), BMD by DXA, abdominal subcutaneous and visceral fat, and beta-cell function and insulin sensitivity. RESULTS: Results were available for 37 subjects who completed the baseline and 1-year evaluations. At 12 months, BM fat increased with pioglitazone (absolute change, +4.1%, p = 0.03), whereas BM fat content in the placebo group decreased non-significantly (-3.1%, p = 0.08) (p = 0.007 for the pioglitazone-placebo response difference). Total hip BMD declined in the pioglitazone group (-1.4%) and increased by 0.8% in the placebo group (p = 0.03 between groups). The change in total hip BMD was inversely and significantly correlated with the change in BM fat content (Spearman rho = -0.56, p = 0.01) in the pioglitazone group, but not within the placebo group (rho = -0.29, p = 0.24). Changes in BM fat with pioglitazone were predominantly observed in female vs. male subjects. CONCLUSIONS: Pioglitazone use for 12 months compared with placebo is associated with significant increase in BM fat content at the femoral neck, accompanied by a small but significant decrease in total hip BMD.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Pop LM, Lingvay I, Yuan Q, et al. Impact of pioglitazone on bone mineral density and bone marrow fat content. Osteoporos Int. 2017. PMID: 28735463. doi:10.1007/s00198-017-4164-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。